Sun Pharmaceutical Industries Limited has reported consolidated financial results for the period ended June 30, 2024.

Sun Pharmaceutical Industries has posted net profit of Rs. 2,835.62 crores for the period ended June 30, 2024 as against net profit of Rs. 2,654.58 crores for the period ended March 31, 2024. The company posted net profit of Rs. 2,022.54 crores for the period ended June 30, 2023.

Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024 as compared to Rs. 12,588.84 crores during the period ended March 31, 2024. The company reported total income of Rs. 12,145.28 crores during the period ended June 30, 2023.

Dilip Shanghvi, Chairman and Managing Director of the Company said, “Sun has recently attained several milestones with the approval of Leqselvi in the US, the filing of Nidlegy in Europe and the completion of acquisition of Taro minority shares. These steps advance our innovative as well as generic business offerings, and will help us serve patients better.”